Fate Therapeutics, Inc.
A San Diego biotech that grows "off-the-shelf" cell therapies for cancer and autoimmune disease. Using induced pluripotent stem cells — adult cells rewound to an early, flexible state — it programs batches of immune cells (natural killer and T cells) that can be stored and given to many patients, unlike therapies made from each person's own cells. Founded in 2007 by stem-cell scientists, the name comes from its mission to "direct the fate" of cells into specific immune fighters. Its ticker symbol on the stock market is fittingly FATE.
Granted 11.3K · Bought 7.05M · Sold 644.0K
Bought 833.3K
Bought 833.3K · Sold 1.33M
Bought 833.3K
Bought 833.3K
Bought 833.3K
Granted 36.3K · Bought 459.3K
Granted 918.8K · Sold 311.0K
Granted 1.19M · Sold 569.3K
Granted 1.21M · Sold 842.2K
Granted 65.0K · Sold 6.0K
Granted 71.4K · Bought 141.3K · Sold 32.9K
Granted 101.8K · Sold 29.2K
Granted 130.8K · Sold 7.1K
Granted 182.6K · Sold 81.1K
Granted 100.0K
Granted 212.3K · Sold 173.9K
Granted 11.3K · Sold 1.4K
Granted 64.9K
Bought 56.4K
Granted 9.1K · Bought 37.6K
Granted 45.0K · Sold 3.9K
Granted 36.3K
Granted 40.4K · Sold 10.0K
Granted 11.3K
Granted 11.3K · Sold 672
Granted 11.3K · Sold 841
Granted 11.3K · Sold 1.5K
Granted 13.4K · Sold 4.7K
Granted 25.2K · Sold 29.5K
Granted 3.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Green Jeremy +1 co-filerDirector, 10% owner · 21 transactions | — | 38.85Mas of Dec 2024 | 11.3K | 7.05M | 644.0K |
| Polaris Venture Management Co. V, L.L.C. +4 co-filers10% owner · 16 transactions | — | 9.84Mas of Oct 2013 | — | 833.3K | — |
| Nashat AmirDirector · 100 transactions | — | 7.04Mas of Aug 2019 | — | 833.3K | 1.33M |
| Ovp Venture Partners VII LP +1 co-filer10% owner · 6 transactions | — | 5.75Mas of Oct 2013 | — | — | — |
| Arch Venture Fund VI LP +4 co-filers10% owner · 4 transactions | — | 2.47Mas of Oct 2013 | — | 833.3K | — |
| Venrock Associates V LP +5 co-filers10% owner · 5 transactions | — | 2.47Mas of Oct 2013 | — | 833.3K | — |
| Nelsen RobertDirector, 10% owner · 4 transactions | — | 1.51Mas of Oct 2013 | — | 833.3K | — |
| Rastetter William HDirector · 7 transactions | — | 642.4K | 36.3K | 459.3K | — |
| Valamehr BahramPresident and CEO, Director · 75 transactions | — | 635.8K | 918.8K | — | 311.0K |
| Tahl CindySee Remarks · 84 transactions | — | 628.2K | 1.19M | — | 569.3K |
| Wolchko J ScottPresident and CEO, Director · 132 transactions | — | 371.2Kas of Jan 2024 | 1.21M | — | 842.2K |
| Bressi Jerome CharlesSee Remarks · 2 transactions | — | 335.2Kas of Jan 2025 | 65.0K | — | 6.0K |
| Mendlein JohnDirector · 10 transactions | — | 311.2Kas of Jan 2023 | 71.4K | 141.3K | 32.9K |
| Chu Yu-WayeChief Medical Officer · 19 transactions | — | 140.7Kas of Apr 2023 | 101.8K | — | 29.2K |
| Plavsic MarkChief Technical Officer · 5 transactions | — | 123.7Kas of Jan 2023 | 130.8K | — | 7.1K |
| Dulac Edward J IIIChief Financial Officer · 23 transactions | — | 101.5Kas of Mar 2024 | 182.6K | — | 81.1K |
| Adawi KamalChief Financial Officer · 2 transactions | — | 100.0K | 100.0K | — | — |
| Shoemaker Daniel DChief Scientific Officer · 40 transactions | — | 79.4Kas of Mar 2021 | 212.3K | — | 173.9K |
| Coughlin TimothyDirector · 3 transactions | — | 66.3Kas of Jun 2022 | 11.3K | — | 1.4K |
| Abbot StewartChief Development Officer · 4 transactions | — | 64.9Kas of May 2018 | 64.9K | — | — |
| Coughlin Timothy PDirector · 1 transaction | — | 56.4Kas of Nov 2016 | — | 56.4K | — |
| Storgard ChrisChief Medical Officer · 2 transactions | — | 42.6Kas of Feb 2017 | 9.1K | 37.6K | — |
| Powl Brian T.Chief Commercial Officer · 2 transactions | — | 41.1Kas of Jul 2023 | 45.0K | — | 3.9K |
| Epstein Robert SDirector · 3 transactions | — | 36.3K | 36.3K | — | — |
| Weyer ChristianSee Remarks, Director · 6 transactions | — | 30.4Kas of Apr 2015 | 40.4K | — | 10.0K |
| Lee Michael StewartDirector · 2 transactions | — | 11.3Kas of Jun 2022 | 11.3K | — | — |
| Hershberg RobertDirector · 3 transactions | — | 10.7Kas of Jun 2022 | 11.3K | — | 672 |
| Agarwal ShefaliDirector · 4 transactions | — | 10.5Kas of Jun 2022 | 11.3K | — | 841 |
| Jooss KarinDirector · 3 transactions | — | 9.8Kas of Jun 2022 | 11.3K | — | 1.5K |
| Xu YuanDirector · 5 transactions | — | 8.7Kas of Aug 2024 | 13.4K | — | 4.7K |
| Flynn Peter DSee remarks · 21 transactions | — | 6.5Kas of Jan 2015 | 25.2K | — | 29.5K |
| Multani Pratik SChief Medical Officer · 1 transaction | — | 3.0Kas of Jan 2015 | 3.0K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: +7.82M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.